Loading...
•
Sep 30
Repare Therapeutics Q3 2025 Earnings Report
Repare Therapeutics reported Q3 2025 results with revenue of $11.6 million and a return to profitability driven by its Debiopharm licensing deal.
Key Takeaways
Repare Therapeutics returned to profitability in Q3 2025 with $3.3 million in net income, driven by a $11.6 million licensing revenue from Debiopharm. Operating expenses fell significantly due to prior restructuring efforts and the out-licensing of the lunresertib program. The company also recognized a gain from the termination of a collaboration agreement. Cash and equivalents stood at $72.8 million at quarter end.
Generated $11.6 million in revenue from a licensing deal with Debiopharm for lunresertib.
Reported net income of $3.3 million, reversing a net loss of $34.4 million in the same quarter last year.
Reduced operating expenses to $13.9 million from $36.4 million YoY due to restructuring and pipeline reprioritization.
Ended the quarter with $72.8 million in cash and equivalents, providing runway into 2027.
Repare Therapeutics
Repare Therapeutics
Repare Therapeutics Revenue by Geographic Location
Revenue by Geographic Location
Switzerland Revenue
CapyFin.com Forward Guidance
Repare expects to maintain a minimal workforce and sufficient cash runway into 2027 as it prepares for its acquisition by XenoTherapeutics.
Positive Outlook
- Expected closing of acquisition by XenoTherapeutics in Q1 2026.
- Cash runway projected through 2027.
- Continued advancement of RP-3467 and RP-1664 clinical programs.
- Ongoing monetization of out-licensed assets including lunresertib.
- Reduction in operating expenses due to workforce downsizing.
Challenges Ahead
- Pending transaction may create operational uncertainty.
- No ongoing revenue-generating products outside of licensing deals.
- Significant reduction in workforce may limit internal R&D capacity.
- Potential delays in achieving CVR milestones post-acquisition.
- Continued reliance on external partners for clinical development.